Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

121 results about "AdverseEvent" patented technology

Assessing the risk of a major adverse cardiac event in patients with chest pain

Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a control value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from control population. Such comparison can also be used to determine treatment of the patient immediately at presentation in the emergency room.
Owner:THE CLEVELAND CLINIC FOUND

Method of providing pirfenidone therapy to a patient

The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
Owner:INTERMUNE INC

Kit for rapidly detecting warfarin individualized medication related gene SNP sites, and its detection method

The invention relates to a kit for rapidly detecting warfarin individualized medication related gene SNP sites, and its detection method, and belongs to a genetic detection technology in the clinic detection technique of the biomedical field. The genetic typing of two polymorphic sites comprising CYP2C9*3(1061A / C) and VKORC1(-1639G / A) is rapidly and accurately carried out through human peripheral blood DNA drawing, specific PCR amplification by a Taq man probe and fluorescence signal analysis. The invention provides primers, probes and kits which are used for detecting the polymorphic sites, a use of the primers and the probes in the preparation of the kits, and a use of the determination of the warfarin application amount of a patient according to the detection results of the polymorphic sites. The determination use can effectively reduce the generation of the warfarin application amount related adverse events and prevent thrombotic diseases. The detection method can be used for the auxiliary diagnosis and treatment of various patients needing warfarin clinically.
Owner:丁虎 +1

Predictive Biomarkers for CTLA-4 Blockade Therapy and for PD-1 Blockade Therapy

ActiveUS20150118245A1Microbiological testing/measurementAntibody ingredientsPd 1 blockadeIpilimumab
Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.
Owner:H LEE MOFFITT CANCER CENT & RES INST INC

Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

This invention provides, inter alia, a complement-inhibitor-based treatment plan coupled with a risk evaluation and management strategy (“REMS”) and a safety support program (“SSP”) for reinforcing the REMS. The REMS and SPP are implemented using one or more computer devices with software tools programmed to enforce conditions of the REMS and / or prompt follow-ups by registered nurses enrolled in the SSP. The software tool(s) determines whether a prescriber requesting the complement inhibitor has agreed to abide by the REMS, and can prompt a provider of the complement inhibitor to provide updated educational materials to the prescriber at predetermined times or intervals, to monitor the prescriber for compliance with the REMS, and / or to monitor patients for signs of adverse events. Using exemplary embodiments described herein, a risk of adverse events (especially, but not limited to, meningococcal infections) can be managed and an incidence of the adverse events can be reduced.
Owner:ALEXION PHARMA INC

Architecture for machine learning model to leverage hierarchical semantics between medical concepts in dictionaries

A method, a system, and a computer program product are provided. A machine learning model is generated to process adverse event information and produce multiple corresponding medical codes associated with the adverse event information, wherein the multiple medical codes are semantically and hierarchically related in a medical taxonomy. The machine learning model includes multiple parallel output layers, each of which is associated with a corresponding medical code. The machine learning model is trained with training data elements, each of which includes adverse event information mapped to respective multiple medical codes, wherein results from each of the output layers adjusts the machine learning model. After completing the training, information pertaining to an adverse event is applied to the machine learning model to determine the corresponding multiple medical codes within the medical taxonomy.
Owner:MERATIVE US LP

Liver organoid compositions and methods of making and using same

Disclosed are methods of inducing formation of a liver organoid from precursor cells, such as iPSC cells. The disclosed liver organoids may be used for screening for a serious adverse event (SAE), such as liver failure and / or drug induced liver injury (DILI), and / or drug toxicity. The disclosed liver organoids may also be used to treat an individual having liver damage, or for identifying a preferred therapeutic agent.
Owner:JAPAN SCI & TECH CORP

Individual and cohort pharmacological phenotype prediction platform

PendingCN111742370AIdentification is accurate and validMedical data miningHealth-index calculationSubstance abuserIdiopathic disease
For patients who exhibit or may exhibit primary or comorbid disease, pharmacological phenotypes may be predicted through the collection of panomic, physiomic, environmental, sociomic, demographic, andoutcome phenotype data over a period of time. A machine learning engine may generate a statistical model based on training data from training patients to predict pharmacological phenotypes, includingdrug response and dosing, drug adverse events, disease and comorbid disease risk, drug-gene, drug-drug, and polypharmacy interactions. Then the model may be applied to data for new patients to predict their pharmacological phenotypes, and enable decision making in clinical and research contexts, including drug selection and dosage, changes in drug regimens, polypharmacy optimization, monitoring,etc., to benefit from additional predictive power, resulting in adverse event and substance abuse avoidance, improved drug response, better patient outcomes, lower treatment costs, public health benefits, and increases in the effectiveness of research in pharmacology and other biomedical fields.
Owner:RGT UNIV OF MICHIGAN

Intelligent management system and method for adverse events involving patients with heart failure

ActiveCN109192312AImprove the intelligent management process and levelImprove the level ofHealth-index calculationCommunications serverData input
The invention relates to an intelligent management system and method for adverse events involving patients with heart failure and belongs to the field of medical data management. The system comprisesa communication server, a computing cloud server, and one or more clients connected to the computing cloud server; the communication server comprises a data collection module for collecting the data of the patients with heart failure; the computing cloud server comprises an algorithm module which is used for modeling the data of the patient through using a DCC algorithm so as to obtain the analysis result of an adverse event model; and the result display module of the client is used for result output or data input and comprises a result demonstration module used for analysis result output or score input. With the intelligent management system and method of the invention adopted, a defect that an existing system and method fail to manage the adverse events involving patients with heart failure can be eliminated, and the standardization and improvement of the process and level of the intelligent management of the patients with heart failure can be benefitted.
Owner:GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products